Journal Mobile Options
Table of Contents
Vol. 4, No. 3, 2012
Issue release date: September – December
Section title: Published: September 2012
Open Access Gateway
Case Rep Dermatol 2012;4:192–196
(DOI:10.1159/000342953)

Chronic Ulcerative Herpes Simplex Virus Infection of the Vulva

Griffith-Bauer K.a · O’Hearn M.b · Ehst B.D.a
Departments of aDermatology and bMedicine, Oregon Health & Science University, Portland, Oreg., USA
email Corresponding Author

Abstract

Herpes simplex virus infections in HIV-infected individuals can be clinically unusual and difficult to treat due to underlying problems with cell-mediated immunity and the occurrence of antiviral resistance. Additionally, partial or incomplete restoration of immune function may result in chronic ulcerations that require rotational treatments. In this report, we describe the case of a 38-year-old HIV-positive woman who developed the ulcerative form of chronic herpes simplex infection despite highly active antiretroviral therapy and valacyclovir prophylaxis. Repeated intravenous courses of foscarnet and topical cidofovir finally controlled her erosions as her cell-mediated immunity was slowly restored. This case highlights the challenges that still exist in diagnosing and managing this rare presentation of herpes simplex virus

© 2012 S. Karger AG, Basel


  

Key Words

  • Chronic herpes simplex virus
  • HIV
  • Immune reconstitution inflammatory syndrome

  

Author Contacts

Dr Benjamin D. Ehst
Department of Dermatology
Oregon Health & Science University, Mail Code CH16D
3303 SW Bond Avenue, Portland, OR 97239 (USA)
E-Mail ehstb@ohsu.edu

  

Article Information

Published online: September 12, 2012
Number of Print Pages : 5
Number of Figures : 3,

  

Publication Details

Case Reports in Dermatology

Vol. 4, No. 3, Year 2012 (Cover Date: September - December)

Journal Editor: Jemec G.B.E. (Roskilde)
ISSN: 1662-6567 (Print), eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Herpes simplex virus infections in HIV-infected individuals can be clinically unusual and difficult to treat due to underlying problems with cell-mediated immunity and the occurrence of antiviral resistance. Additionally, partial or incomplete restoration of immune function may result in chronic ulcerations that require rotational treatments. In this report, we describe the case of a 38-year-old HIV-positive woman who developed the ulcerative form of chronic herpes simplex infection despite highly active antiretroviral therapy and valacyclovir prophylaxis. Repeated intravenous courses of foscarnet and topical cidofovir finally controlled her erosions as her cell-mediated immunity was slowly restored. This case highlights the challenges that still exist in diagnosing and managing this rare presentation of herpes simplex virus

© 2012 S. Karger AG, Basel


  

Author Contacts

Dr Benjamin D. Ehst
Department of Dermatology
Oregon Health & Science University, Mail Code CH16D
3303 SW Bond Avenue, Portland, OR 97239 (USA)
E-Mail ehstb@ohsu.edu

  

Article Information

Published online: September 12, 2012
Number of Print Pages : 5
Number of Figures : 3,

  

Publication Details

Case Reports in Dermatology

Vol. 4, No. 3, Year 2012 (Cover Date: September - December)

Journal Editor: Jemec G.B.E. (Roskilde)
ISSN: 1662-6567 (Print), eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Article / Publication Details

First-Page Preview
Abstract of Published: September 2012

Published online: 9/12/2012
Issue release date: September – December

Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0

ISSN: (Print)
eISSN: 1662-6567 (Online)

For additional information: http://www.karger.com/CDE


Open Access License / Drug Dosage

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.